scholarly journals Comparative Study of Efficacy and Safety of Coded Unani Formulations–UNIM-001+UNIM-003 with Methoxsalen in Cases of Bars (Vitiligo)

2020 ◽  
Vol 07 (3&4) ◽  
pp. 16-26
Author(s):  
Parvez Khan ◽  
Keyword(s):  
Side Effects ◽  
Comparative Study ◽  
Control Group ◽  
Trial Group ◽  
Efficacy And Safety ◽  
Control Drug ◽  
Comparator Group ◽  
Trial Drug ◽  
Control Methodology ◽  
Patient Department

Background: Vitiligo is a common acquired disorder of skin depigmentation in varying patterns, varying from small maculae’s with scalloping borders to near total depigmentation of body. The prevalence of vitiligo in India has been invariably reported between 0.25% and 4% of dermatology outpatients across studies from India and up to 8.8% in Gujarat and Rajasthan. The study was conducted to compare the coded Unani formulation UNIM-001 (tablet) and UNIM-003 (ointment) with Melanocyl tablet (10mg each) (Methoxsalen) as standard control. Methodology: Sixty Five patients of trial group (UNIM-001+ UNIM-003) and sixty seven patients of control group (Comparator group) of 12-50 years of either sex were selected from patients attending the Out Patient Department (OPD), at RRIUM, Aligarh during 2015-18. The patients were treated for eight months with instructions and are followed every month for efficacy and safety of the drug(s). The CRF was maintained, and post treatmet followup was done at 3 months for the repigmentaion retained by the patient. Result: The UNIM-001 (tablets) and UNIM -003 (ointment) and standard control drug Melanocyl tablets (methoxsalen) showed same results and did not show any side effects. Conclusion: The trial drug and the standard control drugs both possess same anti- vitiligo efficacy and are also safe for the patients.

scholarly journals Clinical Efficacy of Moringa oleifera Lam. Stems Bark in Urinary Tract Infections

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Santosh Kumar Maurya ◽  
Anil Kumar Singh
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Large Scale ◽  
Moringa Oleifera ◽  
Stem Bark ◽  
Control Group ◽  
Trial Group ◽  
Long Time ◽  
Trial Drug ◽  
Tract Infections

Objective. Urinary tract infections (UTI) are the most common problem in clinical practice. Usually they are asymptomatic and are commonly present with distressing symptoms like pain and burning sensation on urination. Antibiotics are widely used to treat UTIs; however, they have their own limitations like resistance, reinfection, and relapses. The purpose of the current study was to evaluate the value of Moringa oleifera Lam. stem bark as a potential medicine for UTIs. Study Design. 30 patients with UTI were randomly divided into two groups with 15 patients in each group. Shigru bark was given to patients of the first group (trial group) and modern medicines were prescribed to the other group of patients. At least three follow-ups are taken in both groups at the end of every week of treatment. Results. After treatment 66.67 % were cured, 13.33 % improved, 13.33% patients have no change, and 6.67% relapsed in trial group and in control group 46.67% were cured, 26.66% improved, 6.67% patients have no change, and 20% relapsed. Interpretation and Conclusion. The trial drug is significant in the management of UTI. This study needs to be done on a large scale and for a long time.

A Comparative Study to verify the Efficacy of Preoperative Intravenous Tranexamic Acid in Control of Tonsillectomy Bleeding

2016 ◽  
Vol 8 (1) ◽  
pp. 22-25 ◽  
Author(s):  
KB Prashanth ◽  
S Abhilash
Keyword(s):  
Side Effects ◽  
Tranexamic Acid ◽  
Comparative Study ◽  
Intravenous Dose ◽  
Control Group ◽  
P Value ◽  
Study Group ◽  
Not Given ◽  
Single Intravenous Dose ◽  
Group I

ABSTRACT Objectives This study was conducted to assess the efficacy of the drug tranexamic acid administered preoperatively in controlling the bleeding during tonsillectomy intraoperatively. Materials and methods A total of 50 patients who underwent tonsillectomy were randomized into two groups. Group I (study group): Intravenous tranexamic acid was given with dose of 10 mg/kg. Group II (control group): Tranexamic acid injection was not given. Intraoperative amount of bleeding was assessed in each case. Results The study group had significant reduction in bleeding and the p-value was <0.05, which was statistically significant, when compared to control group. There were no side effects of the drug observed. Conclusion Single intravenous dose of tranexamic acid at a dose of 10 mg/kg preoperatively is effective in control of tonsillectomy bleeding. How to cite this article Santosh UP, Prashanth KB, Abhilash S. A Comparative Study to verify the Efficacy of Preoperative Intravenous Tranexamic Acid in Control of Tonsillectomy Bleeding. Int J Otorhinolaryngol Clin 2016;8(1):22-25.

scholarly journals Evaluation of the clinical efficacy and safety of nitric oxide synthesized from room air in the postoperative period of cardiac surgery

2021 ◽  
Vol 8 (1) ◽  
pp. 38-50
Author(s):  
A. E. Bautin ◽  
V. D. Selemir ◽  
A. I. Shafikova ◽  
K. Yu. Afanasyeva ◽  
E. S. Kurskova ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Cardiac Surgery ◽  
Side Effects ◽  
Pulmonary Artery ◽  
Clinical Efficacy ◽  
Median Duration ◽  
Postoperative Period ◽  
Main Group ◽  
Control Group ◽  
Efficacy And Safety

Background. Inhaled nitric oxide is a highly selective pulmonary vasodilator, the potential benefits of which include reduced resistance and pressure in the pulmonary artery without systemic arterial hypotension, vasodilation in well-ventilated areas of the lungs, rapid onset of action, and a fairly low incidence of side effects in the therapeutic dose range. Objective. Тс estimate the clinical efficacy and safety of the method for synthesizing nitric oxide from room air in the postoperative period of cardiac surgery. Design and methods. A total of 110 patients were enrolled in the study: 55 patients were included in the main group (nitric oxide was synthesized from room air by AIT-NO-01 device), 55 patients were enrolled in the retrospective control group (nitric oxide was inhaled from the balloon). Inclusion criteria were: undergone heart surgery, mean pulmonary artery pressure (PAPm) ≥ 25 mm Hg., pulmonary artery wedge pressure (PAWP) ≤ 15 mm Hg. Results. After one hour of nitric oxide inhalation in the main group, there were a 35 % decrease in PVR and a 16 % decrease in PAPm. In the control group, there were a decrease in PVR by 40 % and decrease in PAPm by 19 %. Inhalation of nitric oxide did not affect the systemic circulation hemodynamics both in the main and in the control groups. The median duration of the mechanical ventilation (MV) was 7.3 (4.5; 13.8) h and the median length of stay (LOS) in the ICU was 23.2 (21.3; 46) h in the main group. In the retrospective control group, the median duration of MV was 8.2 (5; 14.1) h, and the length of ICU stay was 24 (22; 45.3) h; found no differences between the groups. Conclusion. Nitric oxide synthesized from room air significantly reduces PVR and PAPm in patients with precapillary pulmonary hypertension after cardiac surgery. There were no significant differences in the effect on a pulmonary circulation, clinical data and side effects between the methods of synthesis of nitric oxide from room air and dosing from balloons.

scholarly journals The Efficacy and Safety of Uractiv Control in Overactive Bladder Treatment

2020 ◽  
Vol 71 (1) ◽  
pp. 390-394
Author(s):  
Calin Bogdan Chibelean ◽  
Veronica Ghirca ◽  
Razvan-Cosmin Petca ◽  
Daniel Porav-Hodade ◽  
Ioan Alin Nechifor-Boila ◽  
...  
Keyword(s):  
Placebo Group ◽  
Side Effects ◽  
Overactive Bladder ◽  
Prospective Study ◽  
Treatment Option ◽  
Alternative Treatment ◽  
Control Group ◽  
Efficacy And Safety ◽  
A Prospective Study ◽  
Safe Treatment Option

The aim of this study is to evaluate the efficacy and safety of Uractiv Control as an alternative treatment with no side effects in Overactive Bladder (OAB). We performed a prospective study over a period of 15 months (May 2018- September 2019) in Department of Urology from Targu-Mureș. We included 165 patients diagnosed with OAB wet (129 patients) and dry form (36 patients) which were fully evaluated over a 3-month period of treatment. 48 patients were treated with placebo 1 month and were evaluated by the same parameters like Uractiv Control group. The frequency of micturition during the day and night after the treatment with Uractiv Control was improved compared to placebo group (p=0.0001) and also the loss of urine episodes (p=0.03). Patients did not report any significant side effects of the treatment. Uractiv Control represents a safe treatment option with no side effects and improvement of the storage in OAB.

scholarly journals COMPARATIVE STUDY OF EFFICACY AND SAFETY OF INTRALESIONAL TRIAMCINOLONE ACETONIDE VERSUS INTRALESIONAL 5-FLUOROURACIL VERSUS COMBINATION OF BOTH IN MANAGEMENT OF KELOIDS

2019 ◽  
pp. 1-3
Author(s):  
Himani Tandon ◽  
Anuj Kumar ◽  
P. K. Rathore
Keyword(s):  
Side Effects ◽  
Comparative Study ◽  
Triamcinolone Acetonide ◽  
The Other ◽  
Efficacy And Safety ◽  
Mild Pain

BACKGROUND: keloid is a benign overgrowth of brotic tissue and are aesthetically unacceptable to the patients. Management is difcult and pose a challenge for physicians. This study compares the efcacy and safety of intralesional triamcinolone acetonide, intralesional 5-uorouracil and combination of both in management of keloids. METHOD: Total 60 patients, randomly divided into three groups: A, B, C were subjected to intralesional Triamcinolone acetonide, 5- Fluorouracil and their combination respectively, every 3weeks for 18 weeks and assessed with Vancouver Scoring Scale. RESULTS:Improvement seen in all parameters, maximum with combination of triamcinolone and 5-uorouracil. Major side effects were hypopigmentation with intralesional triamcinolone; pain and hyperpigmentation with intralesional 5- uorouracil and mild pain with combination of two. CONCLUSION: Combination of 5-uorouracil and triamcinolone acetonide seemed to be more effective with lesser side effects than the other two.

scholarly journals A RANDOMISED SINGLE BLIND COMPARATIVE CLINICAL STUDY ON THE EFFICACY OF ANJANI-A FOLKLORE HERB AND KRISHNA TILA KALKA IN THE MANAGEMENT OF PCOS W.S.R TO OLIGOMENORRHOEA

2021 ◽  
pp. 12-16
Author(s):  
Sridevi. M ◽  
B.S.Savadi
Keyword(s):  
Cerebral Cortex ◽  
Clinical Study ◽  
Side Effects ◽  
Modern Science ◽  
Holistic Approach ◽  
Menstrual Irregularity ◽  
Control Drug ◽  
Comparative Clinical Study ◽  
Trial Drug ◽  
Single Blind

Menstruation is the end point of series of events which begin in the cerebral cortex and hypothalamus and ends at the uterus in the hypothalamic pituitary –ovarian uterine axis. Any break in this axis creates Menstrual Problems. PCOS is one such condition associated with abnormal gonadotropic secretion which in turn lead to menstrual irregularity acne and hirsutism- Its prevalence ranging from 2.2% to 26% with age ranging from 18-45 years. In modern science PCOS is managed by down regulating HPO axis using Hormonal Pills which have their own side effects. Therefore complete, comprehensive and holistic approach towards its understanding & treatment is the need of the age. Ayurveda has no direct correlation to PCOS. There are similar condition acc to symptoms are explained under the concept of Pushpaghni, Jathaharini. Here under PCOS w.s.r. to Oligomenorrhoea, interval between menses, duration of flow, amount of flow and other symptoms like pain are considered. The effect of Anjani vati (Trial drug) is compared with Krishna Tila Kalka (Control Drug) in two groups containing 30 patients each.

Intralesional Mycobacterium w Vaccine Versus Cryotherapy in Treatment of Refractory Extragenital Warts

2015 ◽  
Vol 20 (2) ◽  
pp. 123-129 ◽  
Author(s):  
Ashok K. Dhakar ◽  
Sunil Dogra ◽  
Keshavamurthy Vinay ◽  
Rishu Sarangal ◽  
Amrinder J. Kanwar ◽  
...  
Keyword(s):  
Side Effects ◽  
Comparative Study ◽  
Dermatology Life Quality Index ◽  
Quality Index ◽  
Life Quality ◽  
Treatment Modalities ◽  
Efficacy And Safety ◽  
Complete Clearance ◽  
Life Quality Index ◽  
Mycobacterium W

Background: Initial reports of immunotherapy using intralesional Mycobacterium w (Mw) vaccine have documented its useful role in treatment of genital and extragenital warts. Objectives: To compare the efficacy and safety of intralesional Mw vaccine versus cryotherapy in the treatment of refractory extragenital warts. Methods: This was a prospective, randomized, comparative study of 66 patients. The outcome was assessed in terms of complete clearance of warts and change in Dermatology Life Quality Index (DLQI) score. Results: Complete clearance of treated warts was seen in 66.7% (20/30) and 65.5% (19/29) of patients in the Mw and cryotherapy groups, respectively ( P = .769). Clearance of distant warts was significantly ( P = .004) high in the Mw group. Improvement in DLQI was greater in the Mw group. Both treatment modalities were well tolerated, and no major side effects occurred. Conclusions: Mw vaccine and cryotherapy are equally efficacious in treatment of refractory extragenital warts. Mw vaccine has an added advantage of clearance of distant warts.

scholarly journals A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis

2021 ◽  
Author(s):  
Yuqi Shang ◽  
Xi Liu ◽  
Yuanli Chen ◽  
Xiaoqing Luo ◽  
Hongqiong Zhu ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Pulmonary Tuberculosis ◽  
Control Group ◽  
Trial Group ◽  
Newly Diagnosed ◽  
Efficacy And Safety ◽  
Standard Regimen ◽  
Intensive Phase ◽  
One Year ◽  
Negative Conversion

Abstract Background: Moxifloxacin (MFX, M) is currently a second-line antituberculosis drug as initial therapy of pulmonary tuberculosis and one of the main anti-TB drugs in drug-resistant TB, which can kill both intracellular and extracellular Mycobacterium tuberculosis. We started a trial to study the efficacy and safety of the substitution of pyrazinamide and ethambutol with moxifloxacin during the intensive phase of treatment of newly diagnosed susceptive pulmonary tuberculosis. Methods/design: This is a prospective, open, randomized, parallel-controlled, single-center clinical study. The study consists of three phases: a screening period, a treatment period of 6 (or 7) months, and a follow-up period of 1 year. Patients selected for the study will be allocated to the trial group or the control group randomly. The control group will be given six months of a standard regimen(2HRZE/4HR). The trial group will be given a total of six months of treatment with substitution of pyrazinamide and ethambutol with moxifloxacin during the intensive phase(2HRM/4HR). The primary outcome is the rate of adverse outcomes within one year of completion of therapy. The Secondary outcomes include the rate of treatment success at the 2nd, 3rd, 5th and 6th months, the rate of sputum Mtb(Mycobacterium tuberculosis) negative conversion at the 2nd, 3rd, 5th and 6th months, the time of sputum Mtb negative conversion at the 2nd, 3rd, 5th and 6th months, and the number of patients with adverse events within one year of completion of therapy. Comparisons will be performed using two-sided tests with a statistical significance level of 5%.Discussion: This trial will reveal the effectiveness and safety of 2months of use of moxifloxacin instead of pyrazinamide and ethambutol during the intensive phase of treatment for newly diagnosed susceptive pulmonary tuberculosis. If the new regimen including isoniazid, rifampicin and moxifloxacin during the intensive phase of treatment (2HRM/4HR) is no less effective and safe than the standard regimen(2HRZE/4HR), it could be a new alternative treatment for newly diagnosed susceptive pulmonary tuberculosis in the future. Trial registration: ClinicalTrials.gov, NCT04187469. Registered on 5 December 2019.

A Combination of Oral Cabergoline and Double Cloprostenol Injections to Produce Third-Quarter Gestation Termination in the Bitch

2006 ◽  
Vol 42 (5) ◽  
pp. 366-370 ◽  
Author(s):  
Yanina Corrada ◽  
Raúl Rodríguez ◽  
Mariana Tortora ◽  
Daniel Arias ◽  
Cristina Gobello
Keyword(s):  
Treatment Group ◽  
Side Effects ◽  
Untreated Control ◽  
Ultrasound Examination ◽  
Pregnancy Termination ◽  
Control Group ◽  
Efficacy And Safety ◽  
Untreated Control Group

To assess the efficacy and safety of a combined cabergoline and cloprostenol protocol to terminate third-quarter pregnancy, 22 pregnant bitches that ranged from 35 to 45 days after mating were randomly assigned to a treatment group (n=13) or to an untreated control group (n=9). The animals were monitored for 12 days, and pregnancy termination was confirmed by ultrasound examination. Twelve of the 13 treated bitches aborted within 9 days of the initiation of treatment (mean 4.6 days). Only mild side effects were observed. The control animals had normal gestational courses, as did the bitch that did not respond to the therapy. This combination of drugs appeared to be a practical, safe, and efficient abortifacient when used in third-quarter pregnancies.

scholarly journals Study on the role and efficacy of Triphala Ghrita Aschyotan in Vataj Abhishyanda w.r.t Allergic Conjunctivitis

2016 ◽  
Vol 7 (2) ◽  
Author(s):  
Pravin M Bhat
Keyword(s):  
Allergic Conjunctivitis ◽  
Signs And Symptoms ◽  
Control Group ◽  
Allergic Reactions ◽  
Trial Group ◽  
Age Group ◽  
Inclusion Criteria ◽  
Ketotifen Fumarate ◽  
Primary Physicians ◽  
Trial Drug

Allergic conjunctivitis is a common ophthalmic problem predominantly affecting the outdoor workers. The eyes are exposed to different environmental factors. The eye and eyelids are very common sites for allergic reactions. About 50% of conjunctivitis seen by primary physicians is allergic in nature. Vataj Abhishyanda is a clinical entity which can be correlated with allergic conjunctivitis. Triphala Ghrita Aschyotan helps to relieve the symptoms of Vataj Abhishyand w.r.t allergic conjunctivitis. Triphala Ghrita is a Vyadhi Pratyanik Dravya and helpful in topical eye allergies. Aim: To study the role and efficacy of Triphala Ghrita Aschyotan in Vataj Abhishyanda w.r. t. allergic conjunctivitis. Materials and Method: A total 60 patients of the age group 15-60 years presenting with signs and symptoms of Vataj Abhishyanda w.r.t allergic conjunctivitis were selected randomly from OPD of the department of Shalakyatantra, Government Ayurved College, Nanded (M.S.) within inclusion criteria and were treated in two groups. The 30 patients of trial group were treated with Triphala Ghrita Aschyotana and patients of control group in similar number were subjected to Ketotifen Fumarate eye drop. Results: The trial drug Triphala Ghrita is equally effective as compared to Ketotifen eye drop. Trial drug provided more relief in symptoms like Sangharsha (Itching of eyes), which is the parameter of efficacy. Conclusion:Triphala Ghrita Aschyotan is an effective, safe and potent treatment of Vataj Abhishyanda w.r.t allergic conjunctivitis. 

Sign in / Sign up

Export Citation Format

Share Document